131I-Rituximab

N/A

Report date: 2025/09/11 20:00:08

Base Information

Drug Name131I-Rituximab

Drug Alias Name碘[131I]-利妥昔单抗

ClassificationRadiation-emitting products > Nuclides > Iodine > 131IRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell, Marginal Zone

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesKorea Cancer Center Hospital

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKorea Cancer Center Hospital

Active IndicationsN/A

Inactive IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell, Marginal Zone

Other Information

ATC CodeN/A